Citigroup
TARS icon

Citigroup’s Tarsus Pharmaceuticals TARS Stock Holding History

Citigroup’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,000
Closed -$836K – 5774
2024
Q1 		$836K Buy
+23,000
New +$676K ﹤0.01% 3172

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup's TARS Position: Q1 2026 in Review

Citigroup increased its Tarsus Pharmaceuticals (TARS) stake by 4.5% in Q1 2026, buying an estimated $165K and bringing the position to 54,335 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2171.

Citigroup first reported a position in TARS in Q4 2020 and has held it in 22 quarters since. The position peaked at $4.26M in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • Citigroup held 54,335 shares of Tarsus Pharmaceuticals worth $3.81M as of Q1 2026.
  • Citigroup bought 2,364 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $165K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2171 holding.
  • Citigroup first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Tarsus Pharmaceuticals position peaked at $4.26M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.